A Phase 1 interventional study of LY3502970 and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.
Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment, is the only one that started in 2020, is one of 2 in phase 1, and was the 1st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in India, Saudi Arabia, South Africa and 1 more country
Ages 18–65
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 8 more countries
Ages 10–17
Massachusetts General Hospital
Ages 18–79
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 1 started in 2020.
This study's enrollment of 68 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 546 across the 15 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 15 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 160th largest by enrollment of the 232 interventional ones that give a count, is one of 14 that started in 2020, is one of 76 in phase 1, and was the 161st registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing orforglipron in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613307Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | 2027-05 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to learn more about the safety of LY3502970 and any side effects that might be associated with it. Blood tests will be done to measure how much LY3502970 is in the bloodstream, how long it takes the body to eliminate it, and how it affects blood sugar. Participation could last up to 18 weeks and may include up to 14 visits (including three overnight stays) in the study center.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3, 6, 9, 12, 15, 21, 27, 36 and 45 milligrams (mg) LY3502970 administered orally.
Drug: LY3502970
Placebo administered orally.
Drug: Placebo
Administered orally.
Administered orally.
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
An SAE is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect and other situations based on medical judgement. A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
Time frame: Baseline through Follow-up (up to Day 105)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970
Time frame: Day 84: Predose 0.5, 1, 2, 4, 6, 8,12, 24, 48, 96 Hours Postdose
PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours [AUC(0-24)] of LY3502970
PK: area under the concentration versus time curve from time 0 to 24 hours \[AUC(0-24)\] of LY3502970
Time frame: Day 84: Predose 0.5, 1, 2, 4, 6, 8,12, 24 Hours Postdose
Pharmacodynamics (PD): Change From Baseline to Week 12 in Fasting Plasma Glucose (FPG)
Pharmacodynamics (PD): Change from Baseline to Week 12 in Fasting Plasma Glucose (FPG).
Time frame: Baseline, Week 12
PD: Change From Baseline to Week 12 in Fasting Insulin
PD: Change From Baseline to Week 12 in Fasting Insulin.
Time frame: Baseline, Week 12
| Milestone | Placebo QD | 3/6/12/21 mg LY3502970 QD | 3/6/9 mg LY3502970 QD | 3/6/12/15 mg LY3502970 QD | 3/6/12/21/27 mg LY3502970 QD | 3/6/9/21/36/45 mg LY3502970 QD |
|---|---|---|---|---|---|---|
| Started | 17 | 14 | 9 | 10 | 9 | 9 |
| Received at least one dose of study drug | 17 | 14 | 9 | 10 | 9 | 9 |
| Completed | 11 | 6 | 9 | 9 | 8 | 9 |
| Not completed | 6 | 8 | 0 | 1 | 1 | 0 |
| Withdrew: Adverse event | 4 | 5 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 0 | 0 |
An SAE is defined as any untoward medical occurrence that, at any dose: Results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect and other situations based on medical judgement. A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
| Participants | Placebo QD | 3/6/12/21 mg LY3502970 QD | 3/6/9 mg LY3502970 QD | 3/6/12/15 mg LY3502970 QD | 3/6/12/21/27 mg LY3502970 QD | 3/6/9/21/36/45 mg LY3502970 QD |
|---|---|---|---|---|---|---|
| Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug | 1 | 0 | 0 | 0 | 0 | 0 |
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970
| nanograms/milliliter (ng/mL) | 3/6/12/21 mg LY3502970 QD | 3/6/9 mg LY3502970 QD | 3/6/12/15 mg LY3502970 QD | 3/6/12/21/27 mg LY3502970 QD | 3/6/9/21/36/45 mg LY3502970 QD |
|---|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 | 101 ± 28 | 57.9 ± 78 | 97.9 ± 30 | 191 ± 59 | 218 ± 40 |
PK: area under the concentration versus time curve from time 0 to 24 hours \[AUC(0-24)\] of LY3502970
| nanograms hour per milliliter (ng*h/mL) | 3/6/12/21 mg LY3502970 QD | 3/6/9 mg LY3502970 QD | 3/6/12/15 mg LY3502970 QD | 3/6/12/21/27 mg LY3502970 QD | 3/6/9/21/36/45 mg LY3502970 QD |
|---|---|---|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours [AUC(0-24)] of LY3502970 | 1480 ± 23 | 850 ± 73 | 1600 ± 29 | 3120 ± 53 | 3520 ± 29 |
Pharmacodynamics (PD): Change from Baseline to Week 12 in Fasting Plasma Glucose (FPG).
| millimoles per litre (mmol/L) | Placebo QD | 3/6/12/21 mg LY3502970 QD | 3/6/9 mg LY3502970 QD | 3/6/12/15 mg LY3502970 QD | 3/6/12/21/27 mg LY3502970 QD | 3/6/9/21/36/45 mg LY3502970 QD |
|---|---|---|---|---|---|---|
| Pharmacodynamics (PD): Change From Baseline to Week 12 in Fasting Plasma Glucose (FPG) | -1.14 ± 0.47 | -2.02 ± 0.60 | -3.00 ± 0.54 | -2.85 ± 0.55 | -2.42 ± 0.57 | -2.29 ± 0.55 |
PD: Change From Baseline to Week 12 in Fasting Insulin.
| picomoles/litre (pmol/L) | Placebo QD | 3/6/12/21 mg LY3502970 QD | 3/6/9 mg LY3502970 QD | 3/6/12/15 mg LY3502970 QD | 3/6/12/21/27 mg LY3502970 QD | 3/6/9/21/36/45 mg LY3502970 QD |
|---|---|---|---|---|---|---|
| PD: Change From Baseline to Week 12 in Fasting Insulin | -9.71 ± 11.14 | -12.20 ± 13.13 | -5.46 ± 14.48 | 15.16 ± 17.97 | 7.30 ± 17.09 | -1.32 ± 15.63 |
Collected over Baseline through Follow-up (up to Day 105). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo QD | 0/17 (0%) | 1/17 (5.9%) | 7/17 (41.2%) |
| 3/6/12/21 mg LY3502970 QD | 0/14 (0%) | 0/14 (0%) | 10/14 (71.4%) |
| 3/6/9 mg LY3502970 QD | 0/9 (0%) | 0/9 (0%) | 8/9 (88.9%) |
| 3/6/12/15 mg LY3502970 QD | 0/10 (0%) | 0/10 (0%) | 9/10 (90%) |
| 3/6/12/21/27 mg LY3502970 QD | 0/9 (0%) | 0/9 (0%) | 8/9 (88.9%) |
| 3/6/9/21/36/45 mg LY3502970 QD | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Event | Placebo QD | 3/6/12/21 mg LY3502970 QD | 3/6/9 mg LY3502970 QD | 3/6/12/15 mg LY3502970 QD | 3/6/12/21/27 mg LY3502970 QD | 3/6/9/21/36/45 mg LY3502970 QD |
|---|---|---|---|---|---|---|
| Hand fractureInjury, poisoning and procedural complications | 1/17 | 0/14 | 0/9 | 0/10 | 0/9 | 0/9 |
| Skin lacerationInjury, poisoning and procedural complications | 1/17 | 0/14 | 0/9 | 0/10 | 0/9 | 0/9 |
| Lung neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/17 | 0/14 | 0/9 | 0/10 | 0/9 | 0/9 |
| Event | Placebo QD | 3/6/12/21 mg LY3502970 QD | 3/6/9 mg LY3502970 QD | 3/6/12/15 mg LY3502970 QD | 3/6/12/21/27 mg LY3502970 QD | 3/6/9/21/36/45 mg LY3502970 QD |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/17 | 6/14 | 4/9 | 5/10 | 3/9 | 7/9 |
| Decreased appetiteMetabolism and nutrition disorders | 2/17 | 4/14 | 4/9 | 4/10 | 5/9 | 6/9 |
| VomitingGastrointestinal disorders | 0/17 | 2/14 | 5/9 | 5/10 | 5/9 | 5/9 |
| ConstipationGastrointestinal disorders | 0/17 | 0/14 | 3/9 | 0/10 | 1/9 | 0/9 |
| DyspepsiaGastrointestinal disorders | 1/17 | 0/14 | 2/9 | 1/10 | 2/9 | 3/9 |
| EructationGastrointestinal disorders | 0/17 | 0/14 | 1/9 | 3/10 | 2/9 | 2/9 |
| HeadacheNervous system disorders | 1/17 | 0/14 | 2/9 | 3/10 | 1/9 | 2/9 |
| Abdominal distensionGastrointestinal disorders | 0/17 | 1/14 | 0/9 | 1/10 | 2/9 | 2/9 |
| DiarrhoeaGastrointestinal disorders | 3/17 | 1/14 | 0/9 | 1/10 | 2/9 | 1/9 |
| Early satietyGeneral disorders | 0/17 | 0/14 | 1/9 | 2/10 | 1/9 | 2/9 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Placebo QD | 3/6/12/21 mg LY3502970 QD | 3/6/9 mg LY3502970 QD | 3/6/12/15 mg LY3502970 QD | 3/6/12/21/27 mg LY3502970 QD | 3/6/9/21/36/45 mg LY3502970 QD | Total |
|---|---|---|---|---|---|---|---|
| Mean | 56.0 ± 6.0 | 55.3 ± 8.0 | 57.7 ± 6.4 | 59.6 ± 4.6 | 58.8 ± 4.6 | 62.8 ± 4.4 | 57.9 ± 6.3 |
| Sex: Female, Male(Participants) | Placebo QD | 3/6/12/21 mg LY3502970 QD | 3/6/9 mg LY3502970 QD | 3/6/12/15 mg LY3502970 QD | 3/6/12/21/27 mg LY3502970 QD | 3/6/9/21/36/45 mg LY3502970 QD | Total |
|---|---|---|---|---|---|---|---|
| Female | 7 | 4 | 5 | 3 | 2 | 5 | 26 |
| Male | 10 | 10 | 4 | 7 | 7 | 4 | 42 |
| Ethnicity (NIH/OMB)(Participants) | Placebo QD | 3/6/12/21 mg LY3502970 QD | 3/6/9 mg LY3502970 QD | 3/6/12/15 mg LY3502970 QD | 3/6/12/21/27 mg LY3502970 QD | 3/6/9/21/36/45 mg LY3502970 QD | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 8 | 4 | 3 | 3 | 5 | 30 |
| Not Hispanic or Latino | 10 | 6 | 5 | 7 | 6 | 4 | 38 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo QD | 3/6/12/21 mg LY3502970 QD | 3/6/9 mg LY3502970 QD | 3/6/12/15 mg LY3502970 QD | 3/6/12/21/27 mg LY3502970 QD | 3/6/9/21/36/45 mg LY3502970 QD | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 4 | 0 | 2 | 0 | 1 | 9 |
| White | 14 | 10 | 9 | 8 | 9 | 8 | 58 |
| More than one race | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo QD | 3/6/12/21 mg LY3502970 QD | 3/6/9 mg LY3502970 QD | 3/6/12/15 mg LY3502970 QD | 3/6/12/21/27 mg LY3502970 QD | 3/6/9/21/36/45 mg LY3502970 QD | Total |
|---|---|---|---|---|---|---|---|
| United States | 10 | 14 | 4 | 4 | 3 | 5 | 40 |
| Germany | 7 | 0 | 5 | 6 | 6 | 4 | 28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2020 to primary completion in Jul 2021, 9 months.
Results were first posted in May 2026, 4 years 10 months after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 9 months is above that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron